

In vitro screening of bispecific antibody fragments against GABA-A receptors



UNIVERSITY
OF TURKU

Emil Koski¹, Ph.D. Ángel García de Lucas¹, Prof. Urpo Lamminmäki¹ and
Ph.D. Francisco López Picón²

¹Department of Life Technologies, University of Turku

²Turku PET Centre, Turku

MOLECULAR BIOTECHNOLOGY AND DIAGNOSTICS

BACKGROUND

Schizophrenia is a mental disorder that affects person's perception of reality. Symptoms include hallucinations, delusions and paranoia. The pathophysiology is largely unknown.

A prevailing hypothesis is that loss of inhibitory pathways, mainly gamma-aminobutyric acid (GABA) neurotransmitting pathways causes runaway signalling resulting in schizophrenia.




Fig.1 Visual representation of di-scFv antibody fragment

STUDY AIM


- Produce bispecific antibody fragments that target GABA-A receptors and transferrin receptors (Tfr).
- Immuno-characterisation of antibody fragments and verifying their specific binding properties using dissociation-enhanced lanthanide fluorescence immunoassay (DELFA), fluorescent microscopy and confocal microscopy.

MATERIALS AND METHODS

Bispecific di-single chain variable fragment (GABA-A/Tfr di-scFv) antibody fragments are produced using Expi293™ mammalian cells. Produced antibody fragments are evaluated using DELFIA and immunofluorescent microscopy.


DELFA

Di-scFv specificity evaluation



Immunofluorescent microscopy

Transferrin receptor binding



RESULTS AND CONCLUSIONS

Immuno-characterisation of di-scFv construct revealed that the binding is specific against their intended target, extracellular parts of GABA-A receptor's alpha subunit. Di-scFv's GABA-A binding part is working as intended but its affinity is less than we had hoped.




Fig.2 Immuno-characterisation of di-scFv antibody fragment using DELFIA. Peptides 1 and 2 are N-terminal extracellular parts of alpha 1 subunit of GABA-A receptor and are the intended targets. Peptides 2, 4 and 5 are other parts of the alpha 1 and 2 subunits that are not desirable targets.

Next step of this study is to optimize the immunofluorescence for the fluorescent microscopy in order to verify transferrin receptor binding in cells.




Fig.3 Bispecific antibody fragment transferrin induced transcytosis